Cybin Completes FDA Type B Initial Breakthrough Therapy Meeting; Plans For CYB003 Phase 3 Program In Major Depressive Disorder, Expects To Initiate Phase 3 In Late Summer
Cybin完成FDA B型初步突破性療法會議;計劃在重度抑鬱症的CYB003第三階段計劃中,預計在晚夏啓動第三階段。
Cybin Completes FDA Type B Initial Breakthrough Therapy Meeting; Plans For CYB003 Phase 3 Program In Major Depressive Disorder, Expects To Initiate Phase 3 In Late Summer
Cybin完成FDA B型初步突破性療法會議;計劃在重度抑鬱症的CYB003第三階段計劃中,預計在晚夏啓動第三階段。
使用瀏覽器的分享功能,分享給你的好友吧